FDA Launches Probe of Malignancies Linked to CAR-T Therapies 11/28/2023

BMS Expands Cardio Partnership with Avidity in Potential $2.3B Deal 11/28/2023

Argenx’s Vyvgart Fails to Hit Primary, Secondary Endpoints in Phase III Trial 11/28/2023

Acelyrin Flags CRO Errors in Izokibep Program After Late-Stage Failure 11/28/2023

Upstream Bio’s Quest for Effective Best-in-Class Treatments for Allergic Inflammation 11/28/2023

FDA Rejects Aldeyra’s Dry Eye Drug, Cites Need for Additional Trial 11/28/2023

SpringWorks Wins First FDA Approval for Non-Cancerous Desmoid Tumors 11/28/2023

FDA Decisions: First Treatment for Desmoid Tumors and a Dry Eye Rejection for Aldeyra 11/28/2023

A new AI (Artificial Intelligence) tool may make it possible to spare breast cancer patients unnecessary chemotherapy treatments by using a more precise method of predicting their outcomes, reports a new Northwestern Medicine study.

AI evaluations of patient tissues were better at predicting the future course of a patient’s disease than evaluations performed by expert pathologists.

Lidocaine - often used as numbing agent for outpatient medical procedures - activates certain bitter taste receptors through two unique mechanisms that result in cancer cell death, according to researchers from the Perelman School of Medicine at the University of Pennsylvania. Their findings, published in Cell Reports, pave the way for a clinical trial to test the addition of lidocaine to the standard of care therapy for patients with head and neck cancers.

Bayer has added a brand new manufacturing facility to its global supply chain network. The new production plant was inaugurated today at the company's global pharmaceutical headquarters in Berlin, Germany. The facility features state-of-the-art technology, innovative production, and automated processes.

Infections with antibiotic-resistant bacteria are a growing global problem. Part of the solution may lie in copying the bacteria's own weapons. The research environment in Tromsø has found a new bacteriocin, in a very common skin bacterium. Bacteriocin inhibits the growth of antibiotic-resistant bacteria that are often the cause of disease and can be difficult to treat.

Flagship-Founded Microbiome Company Evelo Biosciences Throws in the Towel 11/22/2023

InDex Scraps Phase III Ulcerative Colitis Trial on Disappointing Data 11/22/2023

European Patent Office Declares One of Moderna’s mRNA Patents Invalid 11/22/2023

First ever CRISPR gene therapy approval: What happens next? 11/22/2023

White House and Congress Propose AI Legislation as FDA Continues to Act as AI Regulatory Gatekeeper 11/22/2023

First Rett Treatment Offers Hope to Morell Family at Thanksgiving 11/22/2023

ASH Preview: Darzalex Faspro in Multiple Myeloma, Imbruvica-Venclexta in Mantle Cell Lymphoma 11/22/2023

MorphoSys Forges Ahead Despite Mixed Phase III Myelofibrosis Trial Results 11/22/2023